FDA approval and CE mark for Boston's new balloon catheter
This article was originally published in Clinica
The US FDA has granted premarket approval (PMA) for Boston Scientific's NC Quantum Apex balloon catheter. The Natick, Massachusetts firm has also CE marked the product for sale in Europe, where it plans to launch it this week. US launch is slated to follow next month. The "next-generation" balloon catheter is designed for patients with coronary artery disease undergoing percutaneous coronary intervention, helping to optimise coronary stent deployment by opening arteries blocked by atherosclerosis. The catheter features a new Bi-Segment inner shaft for "improved trackability" and a re-designed tip for greater flexibility, Boston says. It is available in diameters of 2-5mm, and lengths of 6-30mm.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.